v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Cash flows used in operating activities:    
Net loss $ (41,284) $ (35,907)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 6,120 6,833
Depreciation expense 98 156
Accretion of investment discounts, net (609) (1,703)
Charge for In-Process Research and Development ("IPR&D") milestones 4,000  
Other non-cash items 53  
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets 1,433 879
Operating lease right-of-use assets 300 515
Other assets (2) 13
Accounts payable 10 1,871
Accrued expenses (6,674) (11,882)
Operating lease liabilities (327) (599)
Net cash used in operating activities (36,882) (39,824)
Cash flows provided by (used in) investing activities:    
Purchases of property and equipment   (11)
Milestone payments related to IPR&D (4,000)  
Purchases of investments (19,738) (103,648)
Proceeds from maturities of marketable securities 60,000 60,000
Net cash provided by (used in) investing activities 36,262 (43,659)
Cash flows provided by financing activities:    
Proceeds from financings, net of issuance costs   65,577
Proceeds from exercise of stock options and RSUs vesting 7,159 970
Withholding taxes paid on stock-based awards (3,942) (885)
Net cash provided by financing activities 3,217 65,662
Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents (111) 197
Net increase (decrease) in cash, cash equivalents and restricted cash equivalents 2,486 (17,624)
Cash, cash equivalents and restricted cash equivalents, beginning of period 227,636 78,837
Cash, cash equivalents and restricted cash equivalents, end of period 230,122 61,213
Reconciliation of cash, cash equivalents and restricted cash equivalents:    
Cash and cash equivalents 229,136 59,764
Restricted cash equivalents 986 1,449
Total cash, cash equivalents and restricted cash equivalents: $ 230,122 $ 61,213